Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

Biotechnology • Healthcare • Tampa, FL, United States • INTI (OQB)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

813 864 2562 3014 West Palmira Avenue, Tampa, FL 33629-7264, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Investing News Network • Dec 24
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Investing.com • Dec 24
New NLRP3 inhibitors disclosed in Neushen Therapeutics patent - BioWorld MedTech
BioWorld MedTech • Dec 23
Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up - Nasdaq
Nasdaq • Nov 28
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
marketscreener.com • Dec 24

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Inhibitor Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Inhibitor Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Inhibitor Therapeutics, Inc. have?
Inhibitor Therapeutics, Inc. has approximately 3 employees.
What industry is Inhibitor Therapeutics, Inc. in?
Inhibitor Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Inhibitor Therapeutics, Inc. a publicly traded company?
Yes, Inhibitor Therapeutics, Inc. is publicly traded under the ticker symbol INTI on the OQB. The company has a market capitalization of approximately $0.01 billion.
Where is Inhibitor Therapeutics, Inc. headquartered?
Inhibitor Therapeutics, Inc. is headquartered in Tampa, FL, United States at 3014 West Palmira Avenue, Tampa, FL 33629-7264, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.